Ashton Thomas Private Wealth LLC Boosts Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Ashton Thomas Private Wealth LLC lifted its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 106.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 9,062 shares of the medical equipment provider’s stock after purchasing an additional 4,678 shares during the quarter. Ashton Thomas Private Wealth LLC’s holdings in Zimmer Biomet were worth $959,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently modified their holdings of the stock. Callan Family Office LLC purchased a new position in shares of Zimmer Biomet in the 4th quarter worth about $1,153,000. E Fund Management Co. Ltd. raised its position in shares of Zimmer Biomet by 74.6% in the 4th quarter. E Fund Management Co. Ltd. now owns 3,530 shares of the medical equipment provider’s stock worth $373,000 after purchasing an additional 1,508 shares during the last quarter. Candriam S.C.A. raised its position in shares of Zimmer Biomet by 24.9% in the 4th quarter. Candriam S.C.A. now owns 21,769 shares of the medical equipment provider’s stock worth $2,299,000 after purchasing an additional 4,336 shares during the last quarter. Raymond James Financial Inc. purchased a new position in shares of Zimmer Biomet in the 4th quarter worth about $21,234,000. Finally, Arizona State Retirement System raised its position in shares of Zimmer Biomet by 0.4% in the 4th quarter. Arizona State Retirement System now owns 59,152 shares of the medical equipment provider’s stock worth $6,248,000 after purchasing an additional 211 shares during the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Insider Activity at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of the company’s stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total value of $150,649.20. Following the completion of the transaction, the senior vice president now directly owns 8,768 shares in the company, valued at $915,379.20. This represents a 14.13 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 0.95% of the stock is currently owned by corporate insiders.

Zimmer Biomet Trading Up 2.4 %

Shares of NYSE:ZBH opened at $107.87 on Monday. The stock has a 50 day moving average of $105.55 and a 200 day moving average of $107.15. The company has a market cap of $21.47 billion, a PE ratio of 24.24, a price-to-earnings-growth ratio of 1.95 and a beta of 1.04. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43. Zimmer Biomet Holdings, Inc. has a 12-month low of $97.69 and a 12-month high of $133.90.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter in the prior year, the firm posted $2.20 earnings per share. As a group, equities research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be paid a dividend of $0.24 per share. The ex-dividend date is Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.89%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 21.57%.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Royal Bank of Canada lowered their price target on Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. Raymond James decreased their target price on Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. Stifel Nicolaus boosted their target price on Zimmer Biomet from $130.00 to $138.00 and gave the stock a “buy” rating in a research report on Thursday, January 23rd. JMP Securities reissued a “market outperform” rating and issued a $140.00 target price on shares of Zimmer Biomet in a research report on Friday, February 7th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a research report on Friday, February 7th. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, Zimmer Biomet currently has a consensus rating of “Hold” and an average target price of $124.15.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.